The Pro10™ cell line is a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology enables the scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies.
The Pro10™ cells have been fully characterized and licensed for gene therapy development by various biopharmaceutical companies. Viralgen utilizes these cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been specifically optimized for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.
The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors and have significantly contributed to the production of innovative gene therapies. For more information, access the full PDF detailing the HEK293 derived animal component-free suspension Pro10™ cell line, which can help reduce process development time and costs.
